REMINDER: Our focusIR Investor Webinar takes place TONIGHT with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

31 May 2023 11:51

RNS Number : 1896B
Arix Bioscience Plc
31 May 2023
 

Arix Bioscience plc(the "Company")

PDMR notification & Director Shareholding

The Company today announces it has granted an executive award of nil cost options (the "Award") under the Arix Bioscience plc Executive Incentive Plan (the "Plan") to CEO Robert Lyne, which are subject to performance conditions over a three-year period from 1 January 2023 to 31 December 2025 (the "Performance Period"). The Award takes the form of an option to acquire up to 671,800 ordinary shares of £0.00001 each in the Company. Vested Shares are subject to a further two-year holding period, as set out in the Plan. The performance conditions attached to the Award are set out in the Director's Remuneration Report on page 55 of Company's Annual Report & Accounts 2022.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Robert Lyne

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Arix Bioscience plc

b)

 

LEI

 

213800OVT3AHQCXNIX43

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Arix Bioscience plc Ordinary shares of 0.001 pence each

Identification code

GB00BD045071

b)

 

Nature of the transaction

 

Award of nil-cost options under the Arix Bioscience plc Executive Incentive Plan ("EIP")

 c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

 

 

671,800

d)

 

Aggregated information

- Aggregated volume

N/A (Single Transaction)

- Price

N/A (Single Transaction)

e)

 

Date of the transaction

 

30 May 2023

f)

 

Place of the transaction

 

Outside a trading venue

For further information please contact:Kin Company Secretarial Limited, Company Secretary +44 20 8819 6486

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBFLFXXELEBBB
Date   Source Headline
28th May 20214:56 pmEQSTransaction in own shares
27th May 20214:58 pmEQSTransaction in own shares
26th May 20214:53 pmEQSTransaction in own shares
25th May 20215:24 pmEQSTransaction in own shares
24th May 20215:04 pmEQSTransaction in own shares
21st May 20215:09 pmEQSTransaction in own shares
20th May 20215:27 pmEQSTransaction in own shares
20th May 20217:00 amEQSChange of registered office
19th May 20215:06 pmEQSTransaction in own shares
18th May 20215:33 pmEQSTransaction in own shares
18th May 20217:00 amEQSNotice of 2021 Annual General Meeting
17th May 20215:40 pmEQSTransaction in own shares
14th May 20215:02 pmEQSTransaction in own shares
13th May 20215:16 pmEQSTransaction in own shares
12th May 20215:12 pmEQSTransaction in own shares
12th May 20214:35 pmEQSAutolus to present additional data in AUTO1 in IBCL 
11th May 20215:43 pmEQSTransaction in own shares
10th May 20215:21 pmEQSTransaction in own shares
7th May 20215:19 pmEQSTransaction in own shares
6th May 20215:23 pmEQSTransaction in own shares
5th May 20215:16 pmEQSTransaction in own shares
4th May 20215:15 pmEQSTransaction in own shares
4th May 20217:00 amEQSTotal Voting Rights
30th Apr 20214:59 pmEQSTransaction in own shares
30th Apr 20217:00 amEQSOutcome of Strategic Implementation Review and Directorate Change
29th Apr 20215:10 pmEQSTransaction in own shares
28th Apr 20215:14 pmEQSTransaction in own shares
28th Apr 202112:02 pmEQSAmplyx Pharmaceuticals acquired by Pfizer
27th Apr 20215:29 pmEQSTransaction in own shares
27th Apr 20212:00 pmEQSLogicBio announces clinical and corporate updates
26th Apr 20215:32 pmEQSTransaction in own shares
23rd Apr 20215:11 pmEQSTransaction in own shares
22nd Apr 20215:15 pmEQSTransaction in own shares
21st Apr 20215:27 pmEQSTransaction in own shares
20th Apr 20215:31 pmEQSTransaction in own shares
19th Apr 20215:09 pmEQSTransaction in own shares
16th Apr 20215:18 pmEQSTransaction in own shares
15th Apr 20215:09 pmEQSTransaction in own shares
14th Apr 20215:13 pmEQSTransaction in own shares
13th Apr 20215:13 pmEQSTransaction in own shares
12th Apr 20215:23 pmEQSTransaction in own shares
9th Apr 20215:44 pmEQSTransaction in own shares
8th Apr 20215:28 pmEQSTransaction in own shares
8th Apr 20218:19 amRNSProactive One2One Virtual Investor Forum
8th Apr 20217:00 amEQSArix to Present at the Proactive One2One Virtual Investor Forum
7th Apr 20215:47 pmEQSTransaction in own shares
7th Apr 20217:00 amEQSArtios announces collaboration with Novartis to create next generation DDR cancer therapies 
6th Apr 20215:26 pmEQSTransaction in own shares
1st Apr 20215:20 pmEQSTransaction in own shares
1st Apr 20217:00 amEQSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.